Genolution Registers Patent for Honeybee Larva Rearing System

Genolution has completed the registration of a patent for its "honeybee larva rearing system."

According to Genolution on June 4, this patent covers technology designed to enable more stable and efficient rearing of honeybee larvae in laboratory environments. The system features a modular structure that allows for individual management of larvae while replicating natural-like conditions, thereby enhancing the reproducibility and reliability of research processes.

Previously, studies involving honeybee larvae for disease research or toxicity assessment faced limitations in ensuring consistency of results due to variations in individual larval growth and experimental environments. Genolution's honeybee larva rearing system addresses these issues, allowing for its application in a wide range of research areas, including honeybee virus disease studies, pharmaceutical efficacy evaluations, and toxicity and safety assessments.

Notably, this technology can also be applied to research related to Varroa mites—identified as a major cause of honeybee disappearance—making it a potential core research platform for future development of honeybee pharmaceuticals. The significance of this patent registration goes beyond simply securing research equipment technology; it is also a key component of Genolution's strategy to build an RNA-based green bio platform.

Genolution developed and commercialized the world's first RNA-based treatment for honeybee sacbrood virus disease, and the product was designated as an innovative procurement item by the Public Procurement Service in April, with supply now underway. The company has also secured a patent for dsRNA-based pine wood nematode control technology and is currently developing next-generation green bio pipelines such as a Varroa mite treatment and RNA crop protectants.

The company has built capabilities in disease analysis, efficacy validation, formulation development, and production technology based on RNA design and synthesis. With this new patent, Genolution has also secured the core experimental platform technology needed for research and development. This is expected to further advance its R&D system for developing RNA-based veterinary pharmaceuticals and eco-friendly pest control technologies, as well as strengthen its technological competitiveness and intellectual property (IP) base in the green bio sector.

This content was produced with the assistance of AI translation services.